Envista's Q3 sales beat estimates on product launches

Overview

• Dental equipment supplier Envista's Q3 sales of $670 mln beat analyst expectations, with 9.4% core sales growth YoY

• Adjusted EPS for Q3 202 exceeds analysts' estimates, up 167% YoY

• Company repurchased 2.1 mln shares for $41 mln during Q3 2025

Outlook

• Company raises full-year core sales growth guidance to ~4% from 3% to 4%

• Envista maintains 2025 adjusted EBITDA margin guidance at ~14%

• Company raises full-year adjusted EPS guidance to $1.10-$1.15 from $1.05-$1.15

Result Drivers

• NEW PRODUCT LAUNCHES - Co attributes positive growth in all major businesses to several new product launches

• SPARK ALIGNERS - Spark aligners captured market share and achieved profitability, contributing to overall growth

• ENVISTA BUSINESS SYSTEM - Ongoing contributions from the Envista Business System supported operational improvements

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Envista Holdings Corp is $22.00, about 9.2% above its October 29 closing price of $19.98

• The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nPn5367Q8a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)